Beam sues 2 biotechs, alleging theft of base editing trade secrets

Beam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual property

The gene-editing company Beam Therapeutics is alleging that one of its scientists stole intellectual property and used it to co-found a Chinese company that made a deal with VC firms.

Beam sues 2 biotechs, alleging theft of base editing trade secrets

Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges. 

Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress (NASDAQ:BEAM)

Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028–2029, cash runway/dilution risks, valuation vs peers—read now.

Beam sues YolTech and Serapha Bio for allegedly stealing its gene editing tech

Beam Therapeutics, a Cambridge, MA, company developing CRISPR base editing therapies, has sued two Chinese scientists and two biotech companies where they work for allegedly stealing Beam’s trade secrets and copying its technology. The